Myovant Sciences rejects $2.5 billion takeover bid from Sumitovant, Sumitomo Pharma EP News Bureau Oct 3, 2022 Sumitovant, which currently holds approximately 52 per cent of the outstanding shares in Myovant Sciences, and Sumitomo Pharma,…
Myovant Sciences and Pfizer announce US FDA acceptance of supplemental NDA for Myfembree EP News Bureau Jun 4, 2022 The US FDA set a target action date of 29th January, 2023 for this sNDA under the Prescription Drug User Fee Act (PDUFA)
Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise… EP News Bureau May 13, 2022 Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones…
